Ellington Behavioral Health

Ellington Behavioral Health Ellington Behavioral Health is an exceptional group of Mental Health professionals providing extraordinary care.

We are a unique, highly qualified, and experienced mental health team dedicated to providing outstanding care.

11/29/2021

SUBOXONE TREATMENTS: CALL NOW TO SCHEDULE.

SUBOXONE Film is approved for use in both induction and maintenance treatment of opioid dependence in appropriate patients.
For dependence on short-acting opioids, like he**in or prescription painkillers, SUBOXONE Film, which contains buprenorphine and naloxone, may be recommended to help you begin and maintain continuity of treatment
When transitioning from dependence on long-acting opioids, like methadone, a buprenorphine-only medication may be recommended
Induction—you begin your treatment (or restart it if you’ve relapsed) under the supervision of a doctor. For your first dose, you must be in a moderate state of withdrawal. You work with your doctor to reach a dose of SUBOXONE Film that works for you.
Maintenance—Your doctor will help you to transition to the maintenance phase of treatment when you:
Are no longer experiencing withdrawal symptoms
Have minimal to no side effects
Do not have uncontrollable cravings
In the maintenance phase, you may be taking your medication regularly as prescribed. You should comply with all of the elements in your treatment plan including responsibly handling the medication, staying free from illicit drug use, and seeking counseling and/or psychosocial support.
Medical taper—The decision to discontinue therapy with SUBOXONE Film after a period of maintenance should be made as part of a comprehensive treatment plan. It is important that you work with your doctor to determine when the time is right to slowly lower your dose, taking care to minimize withdrawal symptoms. Throughout treatment, you should discuss any concerns you have about relapse with your doctor.

F

10/29/2021

SUBSTANCE ABUSE TREATMENT
There are three different terms used to define substance-related disorders, including substance abuse, substance dependence, and chemical dependence. Treatment for Substance Use Disorders may include:
SUBOXONE Film is approved for use in both induction and maintenance treatment of opioid dependence in appropriate patients.

For dependence on short-acting opioids, like he**in or prescription painkillers, SUBOXONE Film, which contains buprenorphine and naloxone, may be recommended to help you begin and maintain continuity of treatment
When transitioning from dependence on long-acting opioids, like methadone, a buprenorphine-only medication may be recommended
Induction—you begin your treatment (or restart it if you’ve relapsed) under the supervision of a doctor. For your first dose, you must be in a moderate state of withdrawal. You work with your doctor to reach a dose of SUBOXONE Film that works for you.
Maintenance—Your doctor will help you to transition to the maintenance phase of treatment when you:
Are no longer experiencing withdrawal symptoms
Have minimal to no side effects
Do not have uncontrollable cravings
In the maintenance phase, you may be taking your medication regularly as prescribed. You should comply with all of the elements in your treatment plan including responsibly handling the medication, staying free from illicit drug use, and seeking counseling and/or psychosocial support.
Medical taper—The decision to discontinue therapy with SUBOXONE Film after a period of maintenance should be made as part of a comprehensive treatment plan. It is important that you work with your doctor to determine when the time is right to slowly lower your dose, taking care to minimize withdrawal symptoms. Throughout treatment, you should discuss any concerns you have about relapse with your doctor.

10/18/2021

SPRAVATO TREATMENTS (Esketamine)
Spravato is the first approved nasal spray medication, taken along with an oral antidepressant, for adults with TRD. Those who took Spravato and an oral antidepressant experienced greater reduction of depressive symptom's at four weeks compared to those who received a placebo and an oral antidepressant. After 16 weeks of therapy, patients who stayed on Spravato along with an oral antidepressant did better than those who stopped therapy. Please give us a call for more information about spravato.

09/09/2021

We are accepting new patients! Different insurance accepted please call and make an appointment 860-871-5402 opt 2 to be directed straight to me!

Address

16 Main Street
Ellington, CT
06029

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Alerts

Be the first to know and let us send you an email when Ellington Behavioral Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram